Bone News and Research

RSS

VisEn Medical expands FMT imaging platform

VisEn Medical Inc., a leader in fluorescence imaging solutions from research through medicine, announced today that it has expanded its leading FMT imaging platform with an FMT™ Multi-Species Imaging Module, to extend FMT imaging and related applications into larger preclinical animal models. VisEn also announced that it will be presenting new study results from its recently-launched Cat B 750 FAST™ and Annexin-Vivo™ fluorescence imaging agents at the AACR 101st Annual Meeting.

16 Apr 2010

Socioeconomic factors linked to rates and outcomes of stem cell transplantation for AML patients

The socioeconomic status of a country has long been considered a potentially significant factor in the availability of high-quality health-care interventions and even a determinant of long-term patient outcomes. A new study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation reports that in Europe, socioeconomic factors have a direct correlation to the rates and outcomes of stem cell transplantation for patients with acute myeloid leukemia (AML).

16 Apr 2010

Alexion Pharmaceuticals' Soliris NDA for PNH receives approval in Japan

Alexion Pharmaceuticals, Inc. and Alexion Pharma International Sàrl today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the Company's New Drug Application (NDA) for the use of Soliris® (eculizumab) as a treatment for patients in Japan with paroxysmal nocturnal hemoglobinuria (PNH).

16 Apr 2010

New nanotechnology biomedical therapy for joint injuries

Dr. Nirav A. Shah, MD, an orthopaedic sports medicine surgeon affiliated with Palos Community Hospital is the first to design a new nanotechnology biomedical therapy that promotes the growth of new, stronger cartilage to aid in the treatment of joint injuries.

16 Apr 2010

Laquinimod may have neuroprotective properties in addition to anti-inflammatory effects for RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech today announced results from several studies demonstrating that laquinimod, a novel, investigational once-daily oral immunomodulator for relapsing remitting multiple sclerosis (RRMS) may have neuroprotective properties in addition to its anti-inflammatory effects.

16 Apr 2010

Revlimid now available to multiple myeloma patients in Nova Scotia

Following the broadcast on CTV's W5 of the plight of multiple myeloma patient Frank Boyd and his inability to obtain appropriate drug treatment, on March 27, the President of Myeloma Canada, John Lemieux, immediately wrote to the Honourable Maureen MacDonald, Minister of Health of Nova Scotia urging her to implement an interim arrangement to ensure that Revlimid is available to multiple myeloma patients, including Mr. Boyd, in Nova Scotia.

16 Apr 2010

Long-term monitoring and education needed to protect lungs of young patients

St. Jude Children's Research Hospital investigators have identified childhood cancer survivors who are at increased risk for deteriorating lung health, in part due to the lifesaving bone marrow transplants they underwent years earlier.

16 Apr 2010

Novartis Pharma AG initiates second Phase I trial for oral PTH1-34: Emisphere Technologies

Emisphere Technologies, Inc. today announced that Novartis Pharma AG has initiated a second Phase I trial for an oral PTH1-34 which uses Emisphere's Eligen Technology, and is in development for the treatment of postmenopausal osteoporosis. Emisphere Technologies is a biopharmaceutical company that focuses on a unique and improved delivery of pharmaceutical compounds and nutritional supplements using its Eligen Technology.

16 Apr 2010

Certain genetic variations linked to tooth decay, periodontitis

Certain genetic variations may be linked to higher rates of tooth decay and aggressive periodontitis, according to two recently published papers by researchers at the University of Pittsburgh School of Dental Medicine and their collaborators.

16 Apr 2010

Phase I clinical trial of DFMO initiated to treat children with neuroblastoma

A new Phase I clinical trial sponsored by the Vermont Cancer Center at the University of Vermont and Fletcher Allen Health Care has opened to test the investigational drug DFMO, or alpha-difluoromethylornithine, as a treatment for the pediatric cancer neuroblastoma.

15 Apr 2010

New cardiac CT technology promises low radiation exposure and improved image quality

Cardiovascular disease is the leading cause of death globally and a tremendous burden on the healthcare system. Better detection of hardening or clogging of arteries and other blood vessels before symptoms occur is needed.

15 Apr 2010

Investigational treatment with IGIV reduces brain atrophy in Alzheimer's patients

An investigational intervention using naturally ocurring antibodies in human blood has preserved the thinking abilities of a group of mild- to moderate-stage Alzheimer's patients over 18 months and significantly reduced the rate of atrophy (shrinkage) of their brains, according to a study performed at the NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

15 Apr 2010

Successful stem cell therapy performed on CHF patients in Mexico

Bioheart, Inc. announced that treatment with stem cell therapy on two congestive heart failure (CHF) patients was performed successfully at the Hospital Angeles Tijuana, Mexico, through Bioheart's Center of Excellence program with Regenerative Medicine Institute.

15 Apr 2010

Targeted therapy MDV3100 is effective for patients with CRPC: Study

An experimental drug is showing promise for the treatment of men with an aggressive form of advanced prostate cancer. A new multicenter study has concluded that the targeted therapy MDV3100 is safe and effective for patients with castration-resistant prostate cancer, known for its poor prognosis and limited treatment options.

15 Apr 2010

New iVAS inflatable vertebral augmentation system released for VCFs

Stryker's Interventional Spine business unit today announced the release of its iVAS inflatable vertebral augmentation system, a minimally invasive device cleared for use in treating vertebral compression fractures.

15 Apr 2010

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced

Baxter International Inc. and New York-Presbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (marketed as KIOVIG outside of the U.S.) for mild-to-moderate Alzheimer's disease. This marked the first announcement of clinical trial results measuring function and cognition in patients who received uninterrupted GAMMAGARD for a period of 18 months.

From Baxter International Inc. 15 Apr 2010

biospace med raises $18M to accelerate market penetration of EOS imaging system in North America and Europe

biospace med announced today that it has raised $18 million to accelerate market expansion in North America and Europe of the company's FDA-cleared EOS ultra-low-dose 2D/3D imaging system.

15 Apr 2010

Tel Aviv University is bioengineering tissues as an alternative to animal testing

It's illegal for health products with medical formulations to be accepted by the U.S. Food and Drug Administration without tests on animals ― a situation that has serious ethical and moral implications. New research in the field of tissue engineering by Prof. Amit Gefen of Tel Aviv University's Faculty of Engineering holds a promise that far fewer lab animals will be needed for the necessary experimental trials.

15 Apr 2010

ConforMIS' iUni G2 patient-specific knee replacement system receives CE Mark certification

ConforMIS, Inc. announced today that the iUni® G2 has received CE Mark certification, providing regulatory approval for ConforMIS to begin the sale of this products throughout the European Union. The iUni G2 is the next generation of ConforMIS' revolutionary patient-specific knee replacement system, and remains the only patient-specific unicompartmental knee resurfacing implant on the market.

15 Apr 2010

Biomet's third fiscal quarter net sales increase 9%

Biomet, Inc. announced today financial results for its third fiscal quarter ended February 28, 2010.

15 Apr 2010

Bone News and Research

VisEn Medical expands FMT imaging platform

Socioeconomic factors linked to rates and outcomes of stem cell transplantation for AML patients

Alexion Pharmaceuticals' Soliris NDA for PNH receives approval in Japan

New nanotechnology biomedical therapy for joint injuries

Laquinimod may have neuroprotective properties in addition to anti-inflammatory effects for RRMS

Revlimid now available to multiple myeloma patients in Nova Scotia

Long-term monitoring and education needed to protect lungs of young patients

Novartis Pharma AG initiates second Phase I trial for oral PTH1-34: Emisphere Technologies

Certain genetic variations linked to tooth decay, periodontitis

Phase I clinical trial of DFMO initiated to treat children with neuroblastoma

New cardiac CT technology promises low radiation exposure and improved image quality

Investigational treatment with IGIV reduces brain atrophy in Alzheimer's patients

Successful stem cell therapy performed on CHF patients in Mexico

Targeted therapy MDV3100 is effective for patients with CRPC: Study

New iVAS inflatable vertebral augmentation system released for VCFs

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced

biospace med raises $18M to accelerate market penetration of EOS imaging system in North America and Europe

Tel Aviv University is bioengineering tissues as an alternative to animal testing

ConforMIS' iUni G2 patient-specific knee replacement system receives CE Mark certification

Biomet's third fiscal quarter net sales increase 9%

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News